| Study | Model Type | Models / Systems Used | Key Numeric Outcomes |
|---|---|---|---|
| LDOC1βclathrin adaptor control of EGFR internalization (IjMS 2024) | Clinical cohort + cell lines | 200 advanced NSCLC patients (100 EGFR-mutant on gefitinib; 100 EGFR-WT on chemotherapy), follow-up 0.4β70.5 months; cell lines A549, PC9, HCC827, U2OS | Cytoplasmic EGFR: WT/high-LDOC1 9.1% vs WT/low 42.2%; mutant/high 12.1% vs mutant/low 59.5%. LDOC1-high/low: EGFR-WT 55/45, EGFR-mutant 58/42. HCC827 gefitinib IC50 rose 1.8β2.3 Β΅M with LDOC1 depletion; osimertinib IC50 unchanged (~0.9 Β΅M); low LDOC1 β shorter OS (p < 0.001) |
| pSTAT3 transactivation of EGFR (ABBS 2024) | Cell lines only | A549, H1975, PC-9, H1299, HEK 293T | No numeric IC50/outcome values reported in the extract; qualitative finding: reduced membrane EGFR enhances nuclear pSTAT3 β EGFR transcription and TKI resistance |
| EGFR GCN vs mutation status (Pathology 2014) | Human tissue cohort | 96 resected lung adenocarcinomas (52 M / 44 F, median age 67, range 30β86) | 34/96 SISH-positive (35%); 31/96 EGFR-mutant (32%); low sensitivity/PPV β GCN not a useful mutation screen. Case-level examples: 8 of 10 tabulated mutants were SISH-negative |
| FUT8βEGFR core fucosylation vs antiviral immunity (Nat Commun 2024) | Cell lines + mouse models | Huh7, Huh7.5.1, HEK293T, EGFR-KO, FUT8-KO lines (n=3 biological replicates); ICR 4R+ mice (Fut8 silencing, n=3/group); C57BL/6J + VSV + 2FF (n=3β4/group) | FUT8 mRNA up 3β10-fold at 6β12 h post-HCV; EGFR N352Q abolishes endocytosis and pJAK1/pSTAT3; FUT8 overexpression raises HCV RNA/NS3; Fut8 silencing or 2FF lowers HCV/VSV replication and raises IFN-I/Ifnb1 |
| CIN85 phosphorylation in EGFR sorting (MBoC 2012) | Cell lines | HeLa, HuH7, SYF MEFs, 3T9 fibroblasts (β₯30 cells/condition quantified) | CIN85-4F: ~80% reduced c-Cbl binding, ~70% reduced EGFR ubiquitination, >50% reduced MVB sorting (p<0.0001), early-endosome retention at 2 h (p<0.0005); WT EGFR ~90% degraded by 90 min vs ~50% retained with 4F; Src re-expression accelerates degradation 3β4-fold in SYF cells |
| EGFR-TKI sensitivity by mutation (JTO 2017 abstract) | Cell lines | PC9 (ex19del), H3255 (L858R), H1975 (G719S+T790M; L861Q+T790M), BID007 (ex20ins), Ba/F3 mutants | H1975 double-mutant IC50 ~100 nM (osimertinib); PC9/H3255 IC50 lower than nazartinib; BID007 ex20ins sensitivity similar between osimertinib and nazartinib |
| EGFR-targeted nanoparticles (J Control Release 2012) | Cell line + xenograft | A431 cells; female nude mice with A431 tumors | Up to 90% internalization of targeted Ni-NPs in A431 cells; ~2-fold higher intratumoral nickel vs untargeted NPs |
| EGFR pathway review (Future Oncol 2011) | Narrative review | Synthesis of NSCLC literature; no new models | No new numeric outcomes; consolidates biomarker evidence (mutations predictive; GCN/protein expression inconsistent) |
Notes on comparability: Direct quantitative comparison is possible only for the IC50 and trafficking measurements above; several studies report qualitative or figure-only values (e.g., PC9 shLDOC1 gefitinib IC50 exact value not stated in text), and the 2017 TKI study reports approximate nM values for a single line only. These gaps limit pooled inference.
Figure: only IC50 values explicitly reported in the extracts are plotted; the H1975 ~100 nM value is converted for scale. PC9 gefitinib/erlotinib IC50 increases with LDOC1 knockdown were reported qualitatively only and are therefore excluded.
Figure: clinical IHC subgroup values from the 200-patient NSCLC cohort, showing the association of low LDOC1 with cytoplasmic (internalized) EGFR.
Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.